Drugs / OA-235i
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05680233 | Mar 2023 → Jul 2024 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Oasis Pharmaceuticals, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OA-235i | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05680233 ↗ |
| Action | Inhibit | “OA-235i, a PAR2 Inhibitor” NCT05680233 ↗ |
| Route | Subcutaneous | “3 participants will receive 4 mg as a single subcutaneous dose” NCT05680233 ↗ |